- Home
- PEGA vs ROIV Comparison
PEGA vs ROIV Comparison
Compare PEGA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | ROIV |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 14.1B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | PEGA | ROIV |
|---|---|---|
| Price | $61.59 | $22.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $66.69 | $24.31 |
| AVG Volume (30 Days) | 1.1M | ★ 7.9M |
| Earning Date | 10-21-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 116.89 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $1,732,325,000.00 | $20,329,000.00 |
| Revenue This Year | $18.29 | N/A |
| Revenue Next Year | $6.66 | $376.94 |
| P/E Ratio | $40.26 | ★ N/A |
| Revenue Growth | ★ 17.00 | N/A |
| 52 Week Low | $29.84 | $8.73 |
| 52 Week High | $68.10 | $23.47 |
Technical Indicators
Market Signals| Indicator | PEGA | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 61.61 |
| Support Level | $57.28 | $21.60 |
| Resistance Level | $59.54 | $23.47 |
| Average True Range (ATR) | 2.00 | 0.88 |
| MACD | 0.29 | 0.06 |
| Stochastic Oscillator | 89.31 | 69.09 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.